Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorcaserin for Cannabis Withdrawal and Self-administration
NCT03253926Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Sep 2017
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cannabis use disorder (CUD) comparing Lorcaserin + Marijuana with Placebo + Marijuana (2 arms). Primary endpoint: Cannabis Self-administration at 14 days. Started Sep 2017; status: completed.
02
Drugs
lorcaserin
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT03253926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03253926.